A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
I-Mab Biopharma US Limited
AstraZeneca
IGM Biosciences, Inc.
EMD Serono
AstraZeneca
Daiichi Sankyo
Eli Lilly and Company
Amgen
Sanofi
Sanofi
Sanofi
AstraZeneca
Sanofi
AstraZeneca
Pfizer
Mast Therapeutics, Inc.